Freeline Therapeutics Holdings plc
Freeline Therapeutics Holdings plc (FRLN) Stock Overview
Explore Freeline Therapeutics Holdings plc’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
28.3M
P/E Ratio
-0.29
EPS (TTM)
$-11.40
ROE
-1.03%
FRLN Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Freeline Therapeutics Holdings plc (FRLN) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $1.40.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.29 and a market capitalization of 28.3M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.